SUVEN LIFE SCIENCES Financial Statement Analysis
|
||
|
The Revenues of SUVEN LIFE SCIENCES have decreased by -12.12% YoY .
The Earnings Per Share (EPS) of SUVEN LIFE SCIENCES has decreased by Negative YoY. |
||
| REVENUES |
| OPERATING MARGIN |
| PROFIT AFTER TAX |
| EPS |
| ROCE |
SUVEN LIFE SCIENCES Last 5 Annual Financial Results
[BOM: 530239|NSE : SUVEN]
| Consolidated | Mar2023 | Mar2022 | Mar2021 | Mar2020 | Mar2019 |
|---|---|---|---|---|---|
| Revenues | ₹12 Cr | ₹13 Cr | ₹14 Cr | ₹286 Cr | ₹625 Cr |
| Expenses | ₹134 Cr | ₹93 Cr | ₹130 Cr | ₹297 Cr | ₹424 Cr |
| Operating Profit (Excl OI) | ₹-122 Cr | ₹-80 Cr | ₹-116 Cr | ₹-11 Cr | ₹202 Cr |
| Other Income | ₹1.60 Cr | ₹7.75 Cr | ₹14 Cr | ₹27 Cr | ₹23 Cr |
| Interest | ₹0.67 Cr | ₹0.94 Cr | ₹0.55 Cr | ₹1.91 Cr | ₹4.63 Cr |
| Depreciation | ₹4.39 Cr | ₹4.35 Cr | ₹4.17 Cr | ₹14 Cr | ₹25 Cr |
| Profit Before Tax | ₹-122 Cr | ₹-77 Cr | ₹-106 Cr | ₹0.16 Cr | ₹196 Cr |
| Profit After Tax | ₹-122 Cr | ₹-72 Cr | ₹-94 Cr | ₹-24 Cr | ₹124 Cr |
| Consolidated Net Profit | ₹-122 Cr | ₹-72 Cr | ₹-94 Cr | ₹-24 Cr | ₹124 Cr |
| Earnings Per Share (Rs) | ₹-5.42 | ₹-8.39 | ₹-5.67 | ₹-7.40 | ₹-1.88 |
| PAT Margin (%) | -873.52 | -1,029.99 | -535.31 | -653.62 | -8.37 |
| ROE(%) | -50.17 | -145.90 | -67.29 | -49.27 | -4.75 |
| ROCE(%) | -49.89 | -117.81 | -60.09 | -54.67 | 0.40 |
| Total Debt/Equity(x) | 0.00 | 0.01 | 0.02 | 0.01 | 0.01 |
Key Financials |
||
| Market Cap | : | ₹ 2,319.3 Cr |
| Revenue (TTM) | : | ₹ 11.9 Cr |
| Net Profit(TTM) | : | ₹ -106.2 Cr |
| EPS (TTM) | : | ₹ -4.9 |
| P/E (TTM) | : | - |
| Industry Peers & Returns | 1W | 1M | 1Y |
| SUVEN LIFE SCIENCES | -3% | -6.8% | 98.6% |
| SUN PHARMACEUTICAL INDUSTRIES | 3% | 2.3% | 68.2% |
| CIPLA | 2.5% | 0.4% | 71.7% |
| DR REDDYS LABORATORIES | -0.2% | -4.9% | 40.3% |
| ZYDUS LIFESCIENCES | 5% | 10.4% | 109.1% |
| DIVIS LABORATORIES | -1.6% | -7% | 23.8% |
| MANKIND PHARMA | NA | NA | NA |
| TORRENT PHARMACEUTICALS | 2.9% | -2.2% | 69% |
| LUPIN | 2.8% | 0% | 147.8% |
SUVEN LIFE SCIENCES Revenues
[BOM: 530239|NSE : SUVEN]
| Y-o-Y | -12.12 % |
| 5 Yr CAGR | -62.90 % |
| Years | Revenues | % Change | |
|---|---|---|---|
| Mar2023 | ₹12 Cr | -12.12 | |
| Mar2022 | ₹13 Cr | -6.50 | |
| Mar2021 | ₹14 Cr | -94.95 | |
| Mar2020 | ₹286 Cr | -54.31 | |
| Mar2019 | ₹625 Cr | - | |
SUVEN LIFE SCIENCES Operating Profit
[BOM: 530239|NSE : SUVEN]
| Y-o-Y | Negative |
| 5 Yr CAGR | Negative |
| Years | Operating Profit | % Change | |
|---|---|---|---|
| Mar2023 | ₹-122 Cr | Negative | |
| Mar2022 | ₹-80 Cr | Negative | |
| Mar2021 | ₹-116 Cr | Negative | |
| Mar2020 | ₹-11 Cr | Negative | |
| Mar2019 | ₹202 Cr | - | |
| Operating Margins | |
|---|---|
| Y-o-Y | Negative |
| 5 Yr CAGR | Negative |
| Years | Operating Margin% | % Change | |
|---|---|---|---|
| Mar2023 | -1032.16% | Negative | |
| Mar2022 | -593.12% | Negative | |
| Mar2021 | -802.75% | Negative | |
| Mar2020 | -3.84% | Negative | |
| Mar2019 | 32.25% | - | |
SUVEN LIFE SCIENCES Profit After Tax
[BOM: 530239|NSE : SUVEN]
| Y-o-Y | Negative |
| 5 Yr CAGR | Negative |
| Years | Profit After Tax | % Change | |
|---|---|---|---|
| Mar2023 | ₹-122 Cr | Negative | |
| Mar2022 | ₹-72 Cr | Negative | |
| Mar2021 | ₹-94 Cr | Negative | |
| Mar2020 | ₹-24 Cr | Negative | |
| Mar2019 | ₹124 Cr | - | |
| PAT Margins | |
|---|---|
| Y-o-Y | Negative |
| 5 Yr CAGR | Negative |
| Years | PAT Margin(%) | % Change | |
|---|---|---|---|
| Mar2023 | -873.52 % | Negative | |
| Mar2022 | -1029.99 % | Negative | |
| Mar2021 | -535.31 % | Negative | |
| Mar2020 | -653.62 % | Negative | |
| Mar2019 | -8.37 % | - | |
SUVEN LIFE SCIENCES Earnings Per Share (EPS)
[BOM: 530239|NSE : SUVEN]
| Y-o-Y | Negative |
| 5 Yr CAGR | Negative |
| Years | EPS | % Change | |
|---|---|---|---|
| Mar2023 | ₹-5.42 | Negative | |
| Mar2022 | ₹-8.39 | Negative | |
| Mar2021 | ₹-5.67 | Negative | |
| Mar2020 | ₹-7.40 | Negative | |
| Mar2019 | ₹-1.88 | - | |
SUVEN LIFE SCIENCES Return on Capital Employed (ROCE)
[BOM: 530239|NSE : SUVEN]
| Y-o-Y | Negative |
| 5 Yr CAGR | Negative |
| Years | ROCE | % Change | |
|---|---|---|---|
| Mar2023 | -49.89% | Negative | |
| Mar2022 | -117.81% | Negative | |
| Mar2021 | -60.09% | Negative | |
| Mar2020 | -54.67% | Negative | |
| Mar2019 | 0.4% | - | |
SUVEN LIFE SCIENCES Share Price vs Sensex
| Current Share Price | : | ₹106.3 |
| Current MarketCap | : | ₹ 2,319.3 Cr |
| Updated EOD on | : | Apr 22,2024 |
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| SUVEN LIFE SCIENCES | -3% |
-6.8% |
98.6% |
| SENSEX | -0.8% |
1.4% |
22.9% |
SUVEN LIFE SCIENCES related INDICES
| BSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| S&P BSE SMALL CAP | 0.3% | 9.5% | 63.2% |
| S&P BSE MIDSMALLCAP | -0.5% | 7.6% | 62.8% |
| S&P BSE ALLCAP | -0.7% | 4.1% | 39.1% |
| S&P BSE HEALTHCARE | -1.4% | 2.6% | 53.4% |
No NSE index found
You may also like the below Video Courses
FAQ about SUVEN LIFE SCIENCES Financials
How the annual revenues of SUVEN LIFE SCIENCES have changed ?
The Revenues of SUVEN LIFE SCIENCES have decreased by -12.12% YoY .
How the Earnings per Share (EPS) of SUVEN LIFE SCIENCES have changed?
The Earnings Per Share (EPS) of SUVEN LIFE SCIENCES has decreased by Negative YoY .
Check out Intrinsic Value of Peers of SUVEN LIFE SCIENCES
Compare Stock Analytics of Peers of SUVEN LIFE SCIENCES
SUN PHARMACEUTICAL INDUSTRIES LTD vs CIPLA LTD vs DR REDDYS LABORATORIES LTD
ZYDUS LIFESCIENCES LTD vs DIVIS LABORATORIES LTD vs
SUN PHARMACEUTICAL INDUSTRIES LTD vs CIPLA LTD vs DR REDDYS LABORATORIES LTD
ZYDUS LIFESCIENCES LTD vs DIVIS LABORATORIES LTD vs
